跳至主要内容
临床试验/ISRCTN99811594
ISRCTN99811594已完成3 期

A randomised phase III trial to determine the role of FluoroDeoxyGlucose-Positron Emission Tomography imaging in clinical stages Ia/IIa Hodgkin's disease

eukaemia Research Fund (UK)0 个研究点目标入组 571 人开始时间: 2003年10月21日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
571

研究概览

简要总结

2015 Results article in https://www.ncbi.nlm.nih.gov/pubmed/25901426 results (added 14/02/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged 16 - 75 years, either sex
  • 2. Histologically confirmed Hodgkin's disease (histology will be reviewed retrospectively by Professor A Jack at the Haematological Malignancy Diagnostic Service in Leeds but please note that this is not required before trial entry)
  • 3. Clinical stages Ia/IIa above the diaphragm with no mediastinal bulk (defined as maximum transverse diameter of mediastinal mass: internal thoracic diameter at level of D5/6 interspace greater than 0.33). Bulky disease at other sites (defined as nodal mass with transverse diameter greater than 10 cm) is acceptable.
  • 4. No previous treatment for Hodgkin's disease
  • 5. No previous malignancy excepting appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • 6. No contraindications to chemotherapy or radiotherapy
  • 7. Patients with reproductive potential: a willingness to use contraception from entry into the study for a period of 6 months
  • 8. Written informed consent

排除标准

  • 1. Patients with clinical stage Ia Hodgkin's disease with no clinical or computed tomography (CT) evidence of disease after diagnostic biopsy
  • 2. Pregnant or lactating women
  • 3. Severe underlying illness considered likely to make the trial therapy hazardous (for example severe heart disease or lung fibrosis)
  • 4. Patients unwilling to travel to the nearest PET Centre
  • 5. Patients unable to comply with follow-up arrangements

研究者

发起方
eukaemia Research Fund (UK)

相似试验